Loading JNJ detail
Loading ticker data...
Loading JNJ detail
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue.
The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand.
Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Chart data unavailable
Johnson & Johnson stock is up 17% YTD and over 60% in the past twelve months, reflecting renewed investor confidence but also raising concerns about the sustainability of the rally. In this update on J&J - my first in nearly two years – I'll provide a brief preview of the first-quarter earnings report expected on Tuesday. More importantly, however, I will provide an update on JNJ's drug pipeline and growth prospects.
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision.
Johnson & Johnson has an incredible dividend-increase streak spanning more than 60 years. The company's business is diversified beyond drugs, providing more avenues for growth and increased business stability.
JNJ approaches Q1 results with strong drug growth and MedTech momentum. However, rising biosimilar competition and pricing pressures cloud the outlook.
Besides Wall Street's top-and-bottom-line estimates for Johnson & Johnson (JNJ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Johnson & Johnson (NYSE: JNJ) will release earnings for its first quarter before the opening bell on Tuesday, April 14.
Johnson & Johnson (JNJ) closed at $241.3 in the latest trading session, marking a +1.21% move from the prior day.
As the company heads into its first-quarter earnings report, the narrative has changed from last year's struggles.
Pre-Market Stock Futures: The futures are exploding higher, as, fortunately, President Trump chose not to "end civilization in Iran" and agreed to a two-week pause on attacks on Iran. In contrast, Iran agreed to let ships pass through the Strait of Hormuz. The major indices were mixed after starting Tuesday deep in the red, then rallying in... Here Are Wednesday's Top Wall Street Analyst Research Calls: Coinbase Global, Diamondback Energy, Deere, Doximity, Dutch Bros., Johnson and Johnson, Robinhood Markets, Verizon and More
Braun Stacey Associates Inc. lifted its stake in shares of Johnson and Johnson (NYSE: JNJ) by 9.9% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,856 shares of the company's stock after acquiring an additional 13,411 shares
Dow Jones medical giant Johnson & Johnson, along with AstraZeneca, Burlington Stores and TJX, are in or near buy zones Tuesday.
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson announced launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both closed out 2025 with Q4 earnings and have raised dividends for 63 consecutive years.
A safe stock is a business that can take a punch, keep generating cash flow, keep paying shareholders, and still look stronger a few years later. When debt is low, management has room to maneuver. It can keep investing, protect the dividend, pursue acquisitions, or simply ride out a rough period without making desperate decisions. Safety is not only about defensiveness. Sometimes, the safest company is simply the one executing so well that it keeps compounding no matter what the market feels this quarter.
Aberdeen Group plc lifted its stake in Johnson and Johnson (NYSE: JNJ) by 1.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,538,487 shares of the company's stock after acquiring an additional 47,996 shares during the period. Johnson and Johnson accounts for about
